• STAT+: In potential big step forward for CAR-T, Bristol Myers says its therapy outperformed stem cell transplant in blood cancer

    3 days ago - By STAT

    The treatment known as CAR-T, in which white blood cells are genetically modified to attack blood cancer, is one of the most exciting and expensive in medicine. But it has not been directly compared to standard treatments in a randomized trial - until now.
    Bristol Myers Squibb said Thursday that its CAR-T, Breyanzi, prevented the return of large B-cell lymphoma better than the standard of care treatment, which includes a chemotherapy regimen and a stem cell transplant, in which bone marrow cells are replaced to try to cure blood cancer. Continue to STAT+ to read the full story...
    Read more ...